Metraipolis › archive › dc_6cbbb67f9abf

Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial — Europe PMC PMID:41770089

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41770089
DOI
10.1158/1078-0432.ccr-25-3216
License (as archived)
solo-consultazione
Archived
2026-11-02T22:58:50.315Z
SHA-256 of the archived text
b67b9a95e03cb41973be1f6f9005093fc4169a17beb624aeb1066ca483261cae
Stable URL of this page
https://metraipolis.com/documento/dc_6cbbb67f9abf

How to cite

Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial — Europe PMC PMID:41770089 — Europe PMC (en), https://europepmc.org/article/MED/41770089 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6cbbb67f9abf (Metraipolis archive dc_6cbbb67f9abf, sha256 b67b9a95e03cb41973be1f6f9005093fc4169a17beb624aeb1066ca483261cae)
BibTeX
@misc{dc6cbbb67f9abf,
  title = {Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial — Europe PMC PMID:41770089},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41770089},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6cbbb67f9abf; sha256 b67b9a95e03cb41973be1f6f9005093fc4169a17beb624aeb1066ca483261cae},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41770089. Agents can read the archived copy with the MCP tool read_document.